OBJECTIVE: To investigate the feasibility of coronary stenting in acute myocardial infarction. DESIGN: Prospective observational study. PATIENTS: 80 patients undergoing direct balloon angioplasty for acute myocardial infarction who had coronary Palmaz-Schatz stents implanted during a 3 year study period. Indications for stenting were abrupt reocclusion, large dissection with threatened reocclusion, and failure to achieve brisk flow of contrast by angioplasty alone. INTERVENTIONS: After stenting, 50 patients were treated by conventional anticoagulation and 30 patients received antiplatelet therapy with aspirin and ticlopidine. MAIN OUTCOME MEASURES: Death and subacute reocclusion within two weeks. RESULTS: Coronary stenting fully restored vessel patency in 79 patients (98.8%). 10 of 14 patients with symptoms of Killip class IV on admission were discharged from hospital alive. Three of the 66 patients with symptoms of Killip classes I-III died in hospital. Repeat angiography in 59 of these patients, showed 3 symptomatic and 2 silent reocclusions (reocclusion rate 8.5%). No stent thromboses were detected in patients treated with ticlopidine. CONCLUSIONS: Coronary stenting is a safe and effective treatment for complicated direct balloon angioplasty in acute myocardial infarction. In patients with symptoms of Killip classes I to III the risk of subacute reocclusion is comparable to that of bail-out stenting after elective balloon angioplasty.
OBJECTIVE: To investigate the feasibility of coronary stenting in acute myocardial infarction. DESIGN: Prospective observational study. PATIENTS: 80 patients undergoing direct balloon angioplasty for acute myocardial infarction who had coronary Palmaz-Schatz stents implanted during a 3 year study period. Indications for stenting were abrupt reocclusion, large dissection with threatened reocclusion, and failure to achieve brisk flow of contrast by angioplasty alone. INTERVENTIONS: After stenting, 50 patients were treated by conventional anticoagulation and 30 patients received antiplatelet therapy with aspirin and ticlopidine. MAIN OUTCOME MEASURES: Death and subacute reocclusion within two weeks. RESULTS: Coronary stenting fully restored vessel patency in 79 patients (98.8%). 10 of 14 patients with symptoms of Killip class IV on admission were discharged from hospital alive. Three of the 66 patients with symptoms of Killip classes I-III died in hospital. Repeat angiography in 59 of these patients, showed 3 symptomatic and 2 silent reocclusions (reocclusion rate 8.5%). No stent thromboses were detected in patients treated with ticlopidine. CONCLUSIONS: Coronary stenting is a safe and effective treatment for complicated direct balloon angioplasty in acute myocardial infarction. In patients with symptoms of Killip classes I to III the risk of subacute reocclusion is comparable to that of bail-out stenting after elective balloon angioplasty.
Authors: A Montoya; J Mulet; R Pifarré; G Brynjolfsson; J M Moran; H J Sullivan; R M Gunnar Journal: J Thorac Cardiovasc Surg Date: 1978-02 Impact factor: 5.209
Authors: J H Chesebro; G Knatterud; R Roberts; J Borer; L S Cohen; J Dalen; H T Dodge; C K Francis; D Hillis; P Ludbrook Journal: Circulation Date: 1987-07 Impact factor: 29.690
Authors: R J Simes; E J Topol; D R Holmes; H D White; W R Rutsch; A Vahanian; M L Simoons; D Morris; A Betriu; R M Califf Journal: Circulation Date: 1995-04-01 Impact factor: 29.690
Authors: J B Bedotto; J K Kahn; B D Rutherford; D R McConahay; L V Giorgi; W L Johnson; J H O'Keefe; T M Shimshak; R W Ligon; G O Hartzler Journal: J Am Coll Cardiol Date: 1993-09 Impact factor: 24.094
Authors: J M Sutton; S G Ellis; G S Roubin; C A Pinkerton; S B King; A E Raizner; D R Holmes; D J Kereiakes; E J Topol Journal: Circulation Date: 1994-03 Impact factor: 29.690
Authors: W O'Neill; G C Timmis; P D Bourdillon; P Lai; V Ganghadarhan; J Walton; R Ramos; N Laufer; S Gordon; M A Schork Journal: N Engl J Med Date: 1986-03-27 Impact factor: 91.245
Authors: W R Hermans; D P Foley; B J Rensing; W Rutsch; G R Heyndrickx; N Danchin; G Mast; C Hanet; J M Lablanche; W Rafflenbeul Journal: Am J Cardiol Date: 1993-07-01 Impact factor: 2.778